Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer
Status:
Recruiting
Trial end date:
2021-11-21
Target enrollment:
Participant gender:
Summary
This pilot phase I trial studies the side effects of atezolizumab in treating patients with
cancer following adoptive cell transfer. Immunotherapy with monoclonal antibodies, such as
atezolizumab, may help the body's immune system attack the cancer, and may interfere with the
ability of tumor cells to grow and spread.